Clinical efficacy and tolerability of infliximab in patients with severe ankylosing spondylitis

Abstract

This article is devoted to the effectiveness of the treatment of ankylosing spondylitis (AS), one of the chronic inflammatory disease of the musculoskeletal system. The study included 53 patients with active AS (BASDAI activity index >4) and failure of standard therapy, which included the TNF-a inhibitor infliximab (INF) at a dose of 3-5 mg/kg intravenously for 0, 2, 6 weeks and next every 8 weeks. In patients treated with INF, a positive clinical effect was achieved by indicators BASDAI and BASMI scores, as well as a remarkable positive result in dynamics vertebral mobility index and BASFI score. Tolerability of INF patients was satisfactory.